What are the benefits of the CELLSEARCH® Circulating Tumor Cell Test?

As an adjunct to standard methods of monitoring, the CELLSEARCH® CTC Test provides:

  • An earlier assessment of prognosis than PSA in patients with metastatic prostate cancer*
  • Changes in disease status based on predictive prognosis at any time during the course of disease1-3
  • Added value when standard clinical indicators can be, and may remain, unclear1-3

Monitoring patients with metastatic cancer throughout the course of disease is critical to making informed clinical decisions. However, current methods for monitoring patients with metastatic breast, colorectal, and prostate* cancer are not without limitations, controversies, and uncertainties.1,4-7

Clinical studies have demonstrated that the number of circulating tumor cells correlates to disease prognosis and can provide an important marker for assessing patients’ status throughout the course of disease.1-3

The CELLSEARCH® CTC Test is the first and only clinically validated, FDA-cleared blood test for enumerating circulating tumor cells (CTCs) in patients with metastatic breast, colorectal, and prostate* cancer. The CELLSEARCH® CTC Test acts as a real-time liquid biopsy that predicts prognosis at any time during a patient's course of disease. Testing is easy – using the CellSave Preservative Tube, a blood sample is drawn at the point of care or at one of several laboratories that perform the test; CTCs are captured, analyzed and enumerated using the CELLSEARCH® System. View a list of laboratories that perform the CELLSEARCH® CTC Test to start testing patients.

Tracking your patients with serial CTC testing provides you with important, real-time prognostic information throughout the course of disease.

Review clinical studies and real case studies showing the role of CTC testing in patient treatment

*Metastatic prostate cancer patients were defined as having two consecutive increases in the serum marker prostate-specific antigen above a reference level, despite standard hormonal management. These patients are commonly described as having androgen-independent, hormone-resistant, or castration-resistant prostate cancer. For more information on the intended use and limitations for the CELLSEARCH® Circulating Tumor Cell Test, please refer to the Instructions for Use which can be found at documents.cellsearchctc.com.

  1. Cristofanilli M, Hayes DF, Budd GT, et al. J Clin Oncol. 2005;23:1420-1430.
  2. de Bono JS, Scher HI, Montgomery RB, et al. Clin Cancer Res. 2008;14:6302-6309.
  3. Cohen SJ, Punt CJA, Iannotti N, et al. J Clin Oncol. 2008;26:3213-3221.
  4. Henry NL, Hayes DF. Oncologist. 2006;11:541-552.
  5. Monteil J, Mahmoudi N, Leobon S, et al. Anticancer Res. 2009;29:2563-2568.
  6. Metser U, You J, McSweeney J, Freeman M, Hendler A. Am J Roentgenol. 2010;194:766-771.
  7. Lee DK, Park JH, Kim JH, et al. Korean J Urol. 2010;51:358-361.